Food & Drug Administration (2021) Insulin resistance, Cleveland Clinic (2021) The potential role of incretin-based therapies for polycystic ovary syndrome: A narrative review of the current evidence, Sage Journals (2021) Impact of obesity on infertility in women, Journal of the Turkish-German Gynecological Association (2015) Semaglutide treatment of excessive body weight in obese PCOS patients unresponsive to lifestyle programs, Journal of Clinical Medicine (2023) Semaglutide vs metformin in polycystic ovary syndrome (PCOS), Clinicaltrials.gov (2024) Short-term exenatide treatment leads to significant weight loss in a subset of obese women without diabetes, Diabetes Car e (2012) Liraglutide for weight management: a critical review of the evidence, Obesity Science and Practice (2017) Polycystic ovary syndrome: Common questions and answers, American Family Physician (2023) Insulin resistance in polycystic ovarian syndrome, Cureus ( 2022) Hirsutism, Mayo Clinic (2021) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice
Side Effects Unique to Women on Retatrutide The standard side effect profile nausea, GI changes, injection site reactions affects men and women similarly
Dysesthesia occurred in 22.9% of participants at the 7.2mg dose versus only 6% at the 2.4mg dose and 0.5% with placebo
What it costs Peak uses flat pricing that stays the same as your dose climbs, which removes one of the most common surprises with GLP-1 clinics
Instead of pushing every patient to the maximum dose, clinicians may maintain individuals at lower doses that still produce meaningful metabolic effects
First Four Weeks Initial Retatrutide effects typically appear within the first week of dosing
